Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Equity Ratio (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Equity Ratio for 6 consecutive years, with 0.96 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 0.85% to 0.96 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.96, a 0.85% decrease, with the full-year FY2025 number at 0.96, down 0.85% from a year prior.
  • Equity Ratio was 0.96 for Q4 2025 at Janux Therapeutics, roughly flat from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2021 to a low of 0.88 in Q2 2023.
  • A 5-year average of 0.93 and a median of 0.95 in 2024 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: skyrocketed 206.85% in 2021, then fell 8.71% in 2023.
  • Janux Therapeutics' Equity Ratio stood at 0.96 in 2021, then dropped by 8.64% to 0.88 in 2022, then increased by 2.73% to 0.91 in 2023, then rose by 6.44% to 0.96 in 2024, then fell by 0.85% to 0.96 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Equity Ratio are 0.96 (Q4 2025), 0.95 (Q3 2025), and 0.96 (Q2 2025).